# Management of Signs and Symptoms Associated With Dry Eye Disease

> **NCT04015219** · NA · TERMINATED · sponsor: **BioTissue Holdings, Inc** · enrollment: 3 (actual)

## Conditions studied

- Dry Eye Syndromes

## Interventions

- **DEVICE:** Self retained cryopreserved amniotic membrane
- **OTHER:** lifitegrast ophthalmic solution

## Key facts

- **NCT ID:** NCT04015219
- **Lead sponsor:** BioTissue Holdings, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-18
- **Primary completion:** 2020-10-05
- **Final completion:** 2020-10-05
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** enrollment constraints
- **Last updated:** 2022-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04015219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04015219, "Management of Signs and Symptoms Associated With Dry Eye Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04015219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*